JP2008542359A - 治療的活性を有するベンゾフラン誘導体 - Google Patents

治療的活性を有するベンゾフラン誘導体 Download PDF

Info

Publication number
JP2008542359A
JP2008542359A JP2008514302A JP2008514302A JP2008542359A JP 2008542359 A JP2008542359 A JP 2008542359A JP 2008514302 A JP2008514302 A JP 2008514302A JP 2008514302 A JP2008514302 A JP 2008514302A JP 2008542359 A JP2008542359 A JP 2008542359A
Authority
JP
Japan
Prior art keywords
dimethylheptyl
hexahydro
dibenzofuran
dimethylpentyl
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008514302A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008542359A5 (cg-RX-API-DMAC10.html
Inventor
ヤコバン、アビハイ
グリンスパン、フラビオ
アイシコヴィッヒ、アレクサンダー
ステファン ブロディ、マルクス
− ヨセフ、アヴィ バー
メイリン、シーガル
Original Assignee
ファーモス コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファーモス コーポレイション filed Critical ファーモス コーポレイション
Publication of JP2008542359A publication Critical patent/JP2008542359A/ja
Publication of JP2008542359A5 publication Critical patent/JP2008542359A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
JP2008514302A 2005-05-31 2006-05-31 治療的活性を有するベンゾフラン誘導体 Pending JP2008542359A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68537405P 2005-05-31 2005-05-31
PCT/IL2006/000641 WO2006129318A2 (en) 2005-05-31 2006-05-31 Benzofuran derivatives with therapeutic activities

Publications (2)

Publication Number Publication Date
JP2008542359A true JP2008542359A (ja) 2008-11-27
JP2008542359A5 JP2008542359A5 (cg-RX-API-DMAC10.html) 2009-07-16

Family

ID=37039534

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008514302A Pending JP2008542359A (ja) 2005-05-31 2006-05-31 治療的活性を有するベンゾフラン誘導体

Country Status (9)

Country Link
US (1) US20090054376A1 (cg-RX-API-DMAC10.html)
EP (1) EP1885709A2 (cg-RX-API-DMAC10.html)
JP (1) JP2008542359A (cg-RX-API-DMAC10.html)
KR (1) KR20080019644A (cg-RX-API-DMAC10.html)
CN (1) CN101228146A (cg-RX-API-DMAC10.html)
AU (1) AU2006253734A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0610956A2 (cg-RX-API-DMAC10.html)
CA (1) CA2610274A1 (cg-RX-API-DMAC10.html)
WO (1) WO2006129318A2 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2176208T3 (en) * 2007-07-30 2015-04-27 Zynerba Pharmaceuticals Inc Prodrugs of cannabidiol, compositions containing prodrugs of cannabidiol and methods of use thereof
CN102300568A (zh) * 2008-12-05 2011-12-28 赢泰医药科技发展有限公司 Hif-1蛋白积聚的抑制剂
WO2010091185A2 (en) * 2009-02-05 2010-08-12 Trustees Of Boston College Inhibitors of fructose 1,6-bisphosphatase and methods of use thereof
US8476309B2 (en) 2009-08-20 2013-07-02 The University Of Tennessee Research Foundation Benzofuran cannabinoid compounds and related methods of use
DE102011002934A1 (de) 2011-01-20 2012-07-26 Bayer Schering Pharma Ag CB2 Agonisten zur Behandlung und Vorbeugung der Endometriose
WO2013025984A2 (en) * 2011-08-18 2013-02-21 Temple University Cannabinoid receptor treatments
US9409872B1 (en) * 2015-02-16 2016-08-09 Mark Quang Nguyen Fumarate compounds, pharmaceutical compositions thereof, and methods of use
RU2744758C2 (ru) * 2018-10-19 2021-03-15 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Производные оксимов дибензофуранов, обладающие противосудорожной и нейропротективной активностью
CN109223760B (zh) * 2018-10-31 2021-02-02 广东药科大学 一种苯并呋喃衍生物的用途
CN110251096A (zh) * 2019-05-29 2019-09-20 佛山科学技术学院 一种母猪围产期体温评估方法及系统
RU2747202C2 (ru) * 2019-10-25 2021-04-29 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Средство, улучшающее кровоснабжение ишемизированного мозга
EP4161903A4 (en) * 2020-06-04 2024-05-22 London Pharmaceuticals and Research Corporation RIGID CANNABIDIOL ANALOGUES AS STRONG MODULATORS OF CANNABINOID RECEPTORS AND USES THEREOF
WO2023075339A1 (ko) * 2021-10-27 2023-05-04 주식회사 휴켐바이오 신규한 트리사이클릭 유도체 화합물 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558667A (en) * 1968-11-01 1971-01-26 Sterling Drug Inc Benzofurans from o-phenyl ketoximes
US3931288A (en) * 1972-03-13 1976-01-06 Hoffmann-La Roche Inc. Alkyl esters of 4-chlorophenoxy-4-oxo-cycloalkyl-carboxylic acid
FR2482966A1 (fr) * 1980-05-23 1981-11-27 Cerm Cent Europ Rech Mauvernay 1, 2, 3, 4, 4a, 9b, -hexahydro 4-amino dibenzofurannes, leur procede de preparation et leur application en therapeutique
US4837226A (en) * 1988-04-27 1989-06-06 Warner-Lambert Company Polycyclic amine derivatives useful as cerebrovascular agents
US4960815A (en) * 1988-09-22 1990-10-02 Warner-Lambert Company Isotopically-labeled polycyclic amine derivatives

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN6012025837; ＢＯＲＮＨＥＩＭ，Ｌ．Ｍ．　ｅｔ　ａｌ: 'Ｃｈａｒａｃｔｅｒｉｚａｔｉｏｎ　ｏｆ　ｃａｎｎａｂｉｄｉｏｌ-ｍｅｄｉａｔｅｄ　ｃｙｔｏｃｈｒｏｍｅ　Ｐ４５０　ｉｎａｃｔｉｖａｔｉｏｎ' Ｂｉｏｃｈｅｍｉｃａｌ　Ｐｈａｒｍａｃｏｌｏｇｙ Ｖｏｌ．４５，　Ｎｏ．６, 1993, ｐ．１３２３-１３３１ *
JPN6012025839; ＣＲＯＭＢＩＥ，Ｌ．　ｅｔ　ａｌ: 'Ｔｅｔｒａｈｙｄｒｏｃａｎｎａｂｉｎｏｌｓ　ｂｙ　ｔｅｒｐｅｎｙｌａｔｉｏｎ　ｏｆ　ｏｌｉｖｅｔｏｌ　ｗｉｔｈ　（＋）-ｔｒａｎｓ-２-　ａｎｄ　-３-ｃａｒｅｎｅ　ｅｐｏｘｉｄｅｓ' Ｔｅｔｒａｈｅｄｒｏｎ　Ｌｅｔｔｅｒｓ Ｖｏｌ．２４，　Ｎｏ．３０, 1983, ｐ．３１２９-３１３２ *
JPN6012025841; ＳＲＥＢＮＩＫ，Ｍ． ｅｔ ａｌ: 'Ｒｅａｃｔｉｏｎｓ ｏｆ ｃａｎｎａｂｉｎｏｉｄ ｔｏｓｙｌｈｙｄｒａｚｏｎｅｓ． Ｓｔｅｒｅｏｃｈｅｍｉｃａｌ ａｓｐｅｃｔｓ' Ｔｅｔｒａｈｅｄｒｏｎ Ｖｏｌ．４０， Ｎｏ．１９, 1984, ｐ．３８３９-３８４３ *
JPN6012025846; ＣＡＲＤＩＬＬＯ，Ｂ． ｅｔ ａｌ: 'Ａｌｋｙｌａｔｉｏｎ ｏｆ ｒｅｓｏｒｃｉｎｏｌｓ ｗｉｔｈ ｍｏｎｏｔｅｒｐｅｎｏｉｄ ａｌｌｙｌｉｃ ａｌｃｏｈｏｌｓ ｉｎ ａｑｕｅｏｕｓ ａｃｉｄ． Ｓｙｎｔｈｅｓｉｓ ｏｆ ｎｅｗ ｃａｎ' Ｔｅｔｒａｈｅｄｒｏｎ Ｌｅｔｔｅｒｓ Ｎｏ．１０, 1972, ｐ．９４５-９４８ *
JPN7012001896; ＤＲＩＥＳＳＥＮ，Ｒ．Ａ． ｅｔ ａｌ: 'Ｃａｎｎａｂｉｓ． ＸＸＩＩＩ． Ｓｙｎｔｈｅｓｉｓ ｏｆ ｄｅｕｔｅｒｉｕｍ-ｓｕｂｓｔｉｔｕｔｅｄ ｃａｎｎａｂｉｎｏｉｄｓ' Ｒｅｃｕｅｉｌ： Ｊｏｕｒｎａｌ ｏｆ ｔｈｅ Ｒｏｙａｌ Ｎｅｔｈｅｒｌａｎｄｓ Ｃｈｅｍｉｃａｌ Ｓｏｃｉｅｔｙ Ｖｏｌ．１００， Ｎｏ．９, 1981, ｐ．３４２-３４３ *

Also Published As

Publication number Publication date
CA2610274A1 (en) 2006-12-07
BRPI0610956A2 (pt) 2010-08-03
US20090054376A1 (en) 2009-02-26
WO2006129318A3 (en) 2007-02-08
EP1885709A2 (en) 2008-02-13
WO2006129318A2 (en) 2006-12-07
KR20080019644A (ko) 2008-03-04
CN101228146A (zh) 2008-07-23
AU2006253734A1 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
US9200008B2 (en) Heterocyclic compound and p27Kip1 degradation inhibitor
KR20210143803A (ko) Tead 전사인자의 신규한 소분자 저해제
FR2732017A1 (fr) Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
KR20050013255A (ko) 트리시클릭 스테로이드 호르몬 핵 수용체 조절제
WO2011002520A2 (en) Small molecule inhibitors of parp activity
US20090054376A1 (en) Benzofuran derivatives with therapeutic activities
JP7487949B2 (ja) イミダゾテトラジン化合物
JP2005504736A (ja) 新規な二環式及び三環式カンナビノイド
EP1590321B1 (fr) Derives d' arylalkylcarbamates, leur preparation et leur application en therapeutique
WO1992012144A1 (en) Condensed benzoxa ring compound, production thereof, and pharmaceutical composition containing the same
JP5476587B2 (ja) エストロゲン受容体に対して活性を有する縮合化合物
JP2005518446A (ja) 過剰増殖性障害の処置に有用な縮合三環式複素環
JP2012508250A (ja) キノキサリン系のｌｘｒモジュレーター
EP2294068B1 (fr) DERIVES DE 1,3-DIHYDRO-2H-PYRROLO(3,2-b) PYRIDIN-2-ONE, LEUR PREPARATION ET LEURS APPLICATIONS EN THERAPEUTIQUE
TW201103905A (en) 5-alkynyl-pyridines
KR101739362B1 (ko) 1,2 나프토퀴논 유도체 및 이의 제조방법
AU2003209616B2 (en) Bicyclic CB2 cannabinoid receptor ligands
JP6734294B2 (ja) 線維症及び線維症に関連する状態の処置のための組成物
TWI495640B (zh) 苯並氮呯化合物
AU2008317417A1 (en) Small molecule inhibitors of PARP activity
WO2022002780A1 (en) Tetrazole derivatives as trpa1 inhibitors
JPH10147585A (ja) 含酸素複素環化合物
Jung et al. Design, synthesis, and discovery of stilbene derivatives based on lithospermic acid B as potent protein tyrosine phosphatase 1B inhibitors
HU211554A9 (en) Circulation-active dibenzo/1,5/dioxocin-5-ones
JP2007538102A (ja) 糖尿病の処置に有用な５−アニリノ−４−ヘテロアリールピラゾール誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090601

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120522

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121016